InspireMD reports Q1 EPS (22c) vs (21c) last year

Reports Q1 revenue $1.529M vs $1.511M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “In the first quarter we continued to drive commercial adoption of our technology in our served markets, while laying a strong operational and strategic foundation for upcoming transformational milestones. With a clear roadmap for commercial expansion and a disciplined focus on execution, we’ve built and trained a world-class commercial team-ready to execute at scale upon potential FDA PMA approval. We’re energized by the momentum and confident in the opportunities on the horizon.”